Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | PHASE2 | COMPLETED | 60 | — | — | Mar 1, 2001 | Sep 1, 2008 | Feb 26, 2009 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Open label, oral administration of 2ME2 |
| Name | Type | Description |
|---|---|---|
| 2-methoxyestradiol | DRUG | 800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg. |
Inclusion Criteria: 1. Have plateau phase (patients who have been previously treated with at least one conventional or high-dose chemotherapy who are currently off all therapy for at least 4 weeks and are considered to have stable disease) or relapsed MM. Patients in plateau phase must have M-prote...